Compile Data Set for Download or QSAR
Report error Found 193 Enz. Inhib. hit(s) with Target = 'Apoptosis regulator Bcl-2/Bcl2-associated agonist of cell death [103-127,M117N]'
LigandPNGBDBM577692(US11478451, Example 096 | US11478451, Example 098 ...)
Affinity DataIC50: 1.20E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562386(US11401278, Example 57 | (+)-4-chloro-3,14-diethyl...)
Affinity DataIC50: 1.20E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM562369(US11401278, Example 42 | (−)-4-chloro-14-cyc...)
Affinity DataIC50: 1.20E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM562387(US11401278, Example 58 | (+)-4-chloro-3,14-diethyl...)
Affinity DataIC50: 1.30E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM572166(US11478451, Example 21 | (rac)-4-chloro-3-ethyl-2-...)
Affinity DataIC50: 1.40E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562385(US11401278, Example 56 | (rac)-4-chloro-3,14-dieth...)
Affinity DataIC50: 1.40E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM562391(US11401278, Example 62 | (+)-4-chloro-3-ethyl-7-{3...)
Affinity DataIC50: 1.40E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM572202(US11478451, Example 086 | (rac)-4-chloro-12,12-dif...)
Affinity DataIC50: 1.40E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562382(US11401278, Example 53 | (rac)-4-chloro-14-cyclopr...)
Affinity DataIC50: 1.40E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM562350(US11401278, Example 23 | (rac)-13-Chloro-12-ethyl-...)
Affinity DataIC50: 1.50E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM577683(US11478451, Example 087 | US11478451, Example 089 ...)
Affinity DataIC50: 1.60E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562384(US11401278, Example 55 | (+)-4-chloro-14-cycloprop...)
Affinity DataIC50: 1.60E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM562390(US11401278, Example 61 | (+)-4-chloro-3-ethyl-7-{3...)
Affinity DataIC50: 1.60E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM572180(US11478451, Example 35 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.60E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562388(US11401278, Example 59 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 1.70E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM562334(US11401278, Example 7 | (rac)-12-Ethyl-13-fluoro-1...)
Affinity DataIC50: 1.80E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM577698(US11478451, Example 103 | (rac)-3-chloro-4-ethyl-1...)
Affinity DataIC50: 1.80E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM577706(US11478451, Example 111 | (+)-4′-chloro-3...)
Affinity DataIC50: 1.80E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562363(US11401278, Example 36 | (+)-4-chloro-3-ethyl-7-{3...)
Affinity DataIC50: 1.80E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM577689(US11478451, Example 093)
Affinity DataIC50: 1.80E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572157(US11478451, Example 10 | 4-chloro-3-ethyl-1-[2-(mo...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572192(US11478451, Example 47 | (rac)-4-chloro-3-ethyl-14...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562392(US11401278, Example 63 | (+)-4-chloro-3-ethyl-7-{3...)
Affinity DataIC50: 1.90E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM577663(US11478451, Example 67 | (rac)-4-chloro-11,11,12,1...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562368(US11401278, Example 41 | (rac)-4-chloro-14-cyclopr...)
Affinity DataIC50: 1.90E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM572210(US11478451, Example 081 | US11447504, Example 64 |...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM577717(US11478451, Example 123 | (rac)-4-chloro-3-ethyl-7...)
Affinity DataIC50: 1.90E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562377(US11401278, Example 48 | US11401278, Example 65 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM572192(US11478451, Example 47 | (rac)-4-chloro-3-ethyl-14...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562397(US11401278, Example 68 | (rac)-4-chloro-3-ethyl-7-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM572192(US11478451, Example 47 | (rac)-4-chloro-3-ethyl-14...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572195(US11478451, Example 50 | (rac)-4-chloro-3-methyl-2...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572195(US11478451, Example 50 | (rac)-4-chloro-3-methyl-2...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562406(US11401278, Example 77 | (rac)-13-chloro-12-ethyl-...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM572195(US11478451, Example 50 | (rac)-4-chloro-3-methyl-2...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572186(US11478451, Example 41 | US11447504, Example 41 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572186(US11478451, Example 41 | US11447504, Example 41 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572186(US11478451, Example 41 | US11447504, Example 41 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562393(US11401278, Example 64 | (+)-4-chloro-3-ethyl-7-{3...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM572189(US11478451, Example 44 | (rac)-(11Z)-4-chloro-3-et...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572189(US11478451, Example 44 | (rac)-(11Z)-4-chloro-3-et...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572189(US11478451, Example 44 | (rac)-(11Z)-4-chloro-3-et...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM562377(US11401278, Example 48 | US11401278, Example 65 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:BCL-2/Bad BH3 Peptide (BCL-2 Assay): The assay was initiated by addition of 2 μl of a 2.5-fold concentrated His-BCL-2 solution (usually for a 1 ...More data for this Ligand-Target Pair
In Depth
Date in BDB:
10/23/2022
Entry Details
US Patent

LigandPNGBDBM572205(US11478451, Example 60 | US11447504, Example 60 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572205(US11478451, Example 60 | US11447504, Example 60 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572205(US11478451, Example 60 | US11447504, Example 60 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM577659(US11478451, Example 62 | US11478451, Example 076 |...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572208(US11478451, Example 61 | US11447504, Example 62 | ...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572210(US11478451, Example 081 | US11447504, Example 64 |...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

LigandPNGBDBM572198(US11478451, Example 52 | (rac)-4-chloro-3-ethyl-2-...)
Affinity DataIC50: 2.00E+4nMAssay Description:The dose-dependent inhibition by the compounds described in this invention of the interaction between BCL-2 and the BH3 domain of Bad (both human) wa...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2022
Entry Details
US Patent

Displayed 1 to 50 (of 193 total ) | Next | Last >>
Jump to: